**Application of Biomarkers Alterations in Management of Diseases**

|  |  |
| --- | --- |
| **Dr. Seema Kohli****HOD, Pharmacy,****Kalaniketan Polytechnic College,****Jabalpur, (M.P.), India.** | **Dr. Ankita Alice Singh****Faculty, Pharmacy,****Kalaniketan Polytechnic College,****Jabalpur, (M.P.), India.****Dr. Kaminee Sahu****Professor, Pharmacy,****Gyan Ganga Instt. Of Science and Technology****Jabalpur, (M.P.), India.****Dr. B.K. Jain****Faculty, Pharmacy,****Kalaniketan Polytechnic College,****Jabalpur, (M.P.), India.** |

**Abstract**

Biomarkers have a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Many studies using biomarkers never achieve their full potential because of the failure to adhere to the same rules that would apply for the use of variables that are not biological. The development of any biomarker should precede or go in parallel with the standard design of any epidemiological project or clinical trial. . Biomarkers can be applied to describe observable characteristics of a certain disease and to determine optimal treatments based on these phenotypes, as well as genotypes, thence, they have received substantial attention.

This chapter made endeavored to provide an outline of biomarker uses ,their category and the role played in the management of diseases.

**Key Words:** Biomarkers, Variability ,Validity, Disease.

**I Introduction**

Biological markers (biomarkers) have been defined by Hulka and colleagues [1] as “cellular, biochemical or molecular alterations that are measurable in biological media such as human tissues, cells, or fluids.” More recently, the definition has been broadened to include biological characteristics that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention [2]. In practice, biomarkers include tools and technologies that can aid in understanding the prediction, cause, diagnosis, progression, regression, or outcome of treatment of disease.

Biomarkers of all types have been used by generations of epidemiologists, physicians, and scientists to study human disease. The application of biomarkers in the diagnosis and management of cardiovascular disease, infections, immunological and genetic disorders, and cancer are well known [3]. Their use in research has grown out of the need to have a more direct measurement of exposures in the causal pathway of disease that is free from recall bias, and that can also have the potential of providing information on the absorption and metabolism of the exposures [4]. Neuroscientists have also relied on biomarkers to assist in the diagnosis and treatment of nervous system disorders and to investigate their cause. Blood, brain, cerebrospinal fluid, muscle, nerve, skin, and urine have been employed to gain information about the nervous system in both the healthy and diseased state.

The rapid growth of molecular biology and laboratory technology has expanded to the point at which the application of technically advanced biomarkers will soon become even more feasible [5,6]. Molecular biomarkers will, in the hands of clinical investigators, provide a dynamic and powerful approach to understanding the spectrum of neurological disease with obvious applications in analytic epidemiology, clinical trials and disease prevention, diagnosis, and disease management [7].

**II Use of Biomarker**

Biomarkers are particularly important during any pandemic state since they can enhance the development and approval of new, innovative drugs and biological products, particularly in the field of vaccines. Clinical biomarkers are generally defined as the measurable biological indicators of the presence, severity or type of disease in medical settings.(8) [Strimbu K, Tavel JA. 2010] Biomarkers can be applied to describe observable characteristics of a certain disease and to determine optimal treatments based on these phenotypes, as well as genotypes, thence, they have received substantial attention. (9) [Dobler CC, 2019] In particular, respiratory disease biomarkers, such as those associated with acute respiratory distress syndrome (ARDS), have been associated with increased mortality (IL-8, ICAM-1) and improved survival (nitric oxide).(10) [Jain KK, 2017] These biomarkers play a pivotal role in predicting future complications or severity of disease.

**III Biomarker Pathways and Approach**

Biomarkers make us available a dynamic and dominant approach to considerate the spectrum of neurological disease with applications in observational and analytic epidemiology, randomized clinical trials, screening and diagnosis and prognosis.



Figure 1: Biomarker Pathways

Biomarkers are defined as alterations in the constituents of tissues or body fluids that offer the worth for homogeneous arrangement of a disease and risk factors and the can extend our base information about the underlying pathogenesis of disease.

Such Biomarkers can also reflect the whole spectrum of disease starting the earliest manifestations to the terminal stages.

This chapter elegantly describes and briefing out the major uses of biomarkers in clinical investigation. Careful assessment of the validity of biomarkers is required with respect to the stage of disease. Causes of variability in the measurement of biomarkers ranges from the individual to the laboratory process. Various Issues that affect the alteration of biomarkers have been endeavoured to discuss in the present.

**IV Classification of Biomarker**

Biomarkers have been classified by Perera and Weinstein [3] based on the sequence of events from exposure to disease ([Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC534923/figure/f1/)). Though biomarkers readily lend themselves to epidemiological investigations, they are also useful in the investigation of the natural history and prognosis of a disease. Schulte has outlined the capabilities of biomarkers. In addition to delineating the events between exposure and disease, biomarkers have the potential to identify the earliest events in the natural history, reducing the degree of misclassification of both disease and exposure, opening a window to potential mechanisms related to the disease pathogenesis, accounting for some of the variability and effect modification of risk prediction. Biomarkers can also provide insight into disease progression, prognosis, and response to therapy [11].



**Figure 2: Disease pathway and potential impact of biomarkers.**

****

**Figure 3: Different Category of Biomarkers**

**Prognostic Biomarker**

Prognostic Biomarker can be used to select patients with greater likelihood of having a disease-related endpoint event or a substantial worsening in condition in clinical trials. A biomarker used to identify likelihood of a clinical event, disease recurrence or progression in patients who have the disease or medical condition of interest.

Example:

* Total kidney volume, to select patients with autosomal dominant polycystic kidney disease at high risk for progressive decline in renal function for inclusion in interventional clinical trials.
* Plasma fibrinogen may be used as a prognostic biomarker to select patients with chronic obstructive pulmonary disease at high risk for exacerbation and/or all-cause mortality for inclusion in interventional clinical trials
* C-reactive protein (CRP) level may be used as a prognostic biomarker to identify patients with unstable angina or a history of acute myocardial infarction with a greater likelihood of recurrent coronary artery disease events.

**Diagnostic Biomarker**

A biomarker used to detect or confirm presence of a disease or condition of interest or to identify individuals with a subtype of the disease.

Examples:

* Sweat chloride may be used as a diagnostic biomarker to confirm cystic fibrosis.
* Blood sugar or haemoglobin A1c (HbA1c) may be used as a diagnostic biomarker to identify patients with Type 2 diabetes mellitus (DM)
* Ejection fraction may be used as a diagnostic biomarker in patients with heart failure to identify patients with a subset of disease (those with low ejection fraction or preserved ejection fraction)

Medical practice requires accurate diagnosis of diseases and conditions. Diagnostic biomarkers are used for the critical determination of whether a patient has a particular medical condition for which treatment may be indicated or whether an individual should be enrolled in a clinical trial studying a particular disease.

**Predictive Biomarker:**

A biomarker used to identify individuals who are more likely than similar individuals without the biomarker to experience a favourable or unfavourable effect from exposure to a medical product or an environmental agent.

Examples:

* Certain cystic fibrosis transmembrane conductance regulator (CFTR) mutations may be used as predictive biomarkers in clinical trials evaluating treatment for cystic fibrosis, to select patients more likely to respond to particular treatments.
* Human leukocyte antigen allele (HLA)–B\*5701 genotype may be used as a predictive biomarker to evaluate human immunodeficiency virus (HIV) patients before abacavir treatment, to identify patients at risk for severe skin reactions [11].

**V Contributions of Valid Biomarkers to Clinical Research**

**Capabilities of Biomarkers**

* Delineation of events between exposure and disease
* Establishment of dose-response
* Identification of early events in the natural history
* Identification of mechanisms by which exposure and disease are related
* Reduction in misclassification of exposures or risk factors and disease
* Establishment of variability and effect modification
* Enhanced individual and group risk assessments

**VI Types of biomarkers:**

There are types of biomarkers, like Molecular, histologic, radiographic, and physiologic characteristics are types of biomarkers. The basic examples of types of biomarkers are:

• Blood glucose (molecular)

• Tumour size (radiographic)

• Blood pressure (physiologic)

Biomarkers used in risk prediction, in screening, and as diagnostic tests are well established, and they offer distinct and obvious advantages. The classification of many neurological diseases is based on either standardized clinical criteria or histological diagnoses. Biomarkers also have the potential to identify neurological disease at an early stage, to provide a method for homogeneous classification of a disease, and to extend our knowledge-based concerning the underlying disease pathogenesis. These advantages have direct application to all types of clinical investigation, from clinical trials to observational studies in epidemiology.

### **Intermediate biomarkers**

Some biomarkers represent direct steps in the causal pathway of a disease and are therefore strongly related to disease. Others are related in some indirect way to the cause. There are numerous possibilities to consider. A biomarker could be dependent on another known or unknown factor to cause disease. Thus, it is not the only determinant but it is in the causal pathway and remains strongly related to the disease. The biomarker could also be related to an exposure that has already been identified or represents an alteration caused by the exposure that results in the disease [3].

**VII Biomarker Bio-clinical Testing- Screening, diagnostic tests, and prognosis**

Biomarkers depicting prodromal signs enable earlier diagnosis or allow for the outcome of interest to be determined at a more primitive stage of disease. Blood, urine, and cerebrospinal fluid provide the necessary biological information for the diagnosis. In these conditions, biomarkers are used as an indicator of a biological factor that represents either a subclinical manifestation, stage of the disorder, or a surrogate manifestation of the disease. Biomarkers used for screening or diagnosis also often represent surrogate manifestations of the disease. The potential uses of this class of biomarkers include:

* Identification of individuals destined to become affected or who are in the “preclinical” stages of the illness,
* Reduction in disease heterogeneity in clinical trials or epidemiologic studies,
* Reflection of the natural history of disease encompassing the phases of induction, latency and detection, and
* Target for a clinical trial. The improvement in validity and precision far outweigh the difficulty in obtaining such tissues from patients.

The treatment should be available for those who screen positive and it must be accessible and acceptable. Those who screen positive and are diseased should be allowed access to treatments and those treatments must be adequate and available. It is useful to remember that the main benefit of screening is primary (before onset of symptoms) or secondary (early or prodromal detection) prevention.

Diagnostic tests for neurological diseases are used with increased frequency in clinical research and practice. In the diagnostic effort, collection of information from various sources, some of which includes results from diagnostic tests, helps to achieve the ultimate goal of increasing the probability of a given diagnosis. Clinical tests are also performed, though probably less often, for other reasons such as the following: to measure disease severity, to predict disease occurrence, or to monitor the response to a particular treatment. More importantly, biomarkers for disease easily lend themselves to clinical trials. Another advantage of this type of diagnostic test is the reduction in disease heterogeneity in clinical trials or observational epidemiologic studies, leading to better understanding of natural history of disease encompassing the phases of induction, latency and detection [3].

**VIII Biomarker Variability and Validity**

**Certain facts of Bio Marker variability**

Although biomarkers have numerous advantages, variability is a major concern. Variability applies regardless of whether the biomarker represents an exposure or effect modifier, a surrogate of the disease, or an indication of susceptibility.

* Inter-individual variability can result from the amount of an external exposure or from the way a putative toxin is metabolized. For example, individuals exposed to the same chemical might differ in their ability (or inability) to metabolize the agent, or they may have experienced different types of exposures (in the field as compared with in the office).
* Intra-individual variability is usually related to laboratory errors or other conditions, or exposures unique to the individual. Group variability is also encountered, but this is often the desired outcome of a study. Obviously, it is best when group differences are large. Nonetheless, the ability of a biomarker to distinguish between groups is measured by sensitivity and specificity or similar variance estimates. Consideration of the sources of variability in the measurement of a biomarker decreases the potential for misclassification of the exposure.

While measurement error is always a concern with biomarkers, other important factors may explain individual or group variability. Some workers may always wear protective equipment whereas others may not. Interaction with other exposures, drugs, or effect modifiers can increase or decrease the effect of the biomarker under consideration as an exposure or as a measure of susceptibility. Variability can also be attributed to the effects of factors such as individual diet or other personal characteristics. The amount of dietary fat can influence the biological measurement of lipid-soluble vitamins as well as toxic chemicals. These individual factors must be considered by the investigator to fully establish the major causes of variability in these investigations.

**Certain facts of Bio Marker validity**

Precise numbers are enticing, but they are prone to the same problems as any variable. Reliability, validity, sensitivity, specificity, ascertainment bias, and interpretation of data using biomarkers should be reviewed just as carefully as any other variable. These problems remain whether the biomarker is being used as a variable in a clinical trial or in an epidemiologic study.

Reliability or repeatability is crucial. Laboratory errors can lead to misclassification of exposures or disease if the biomarker is not reliable. Pilot studies should be performed to establish a reasonable degree of reliability. Changes in laboratory personnel, laboratory methods, storage, and transport procedures may all affect the reliability of the biomarkers used in any investigation. Kappa statistics for binary or dichotomous data and intra class correlation coefficients should be used to assess test-retest agreement and consistency.

The evaluation of the validity of a biomarker is complex. Schulte and Perera [13] suggest three aspects of measurement validity:

* Content validity, which shows the degree to which a biomarker reflects the biological phenomenon studied,
* Construct validity, which pertains to other relevant characteristics of the disease or trait, for example other biomarkers or disease manifestations, and
* Criterion validity, which shows the extent to which the biomarker correlates with the specific disease and is usually measured by sensitivity, specificity, and predictive power.

To further evaluate the effect of misclassification of disease, false positives and false negatives as well as positive and negative predictive power should also be estimated. In an ideal situation the biomarker has a clear predictive value but in many cases one needs to be established. The use of receiver-operator characteristic curves can provide the tools necessary to determine the best choice in terms of sensitivity and false-positive rates, particularly when other tests are used [14,15].

Most would agree that screening tests would be very desirable for chronic progressive disorders. One purpose of screening is early detection with the hope of preventing the illness altogether. Many of the methods and concerns related to diagnostic testing apply to screening as well. As with other diagnostic methods, sensitivity and specificity tell us the accuracy of the test but not the probability of disease. For that we need to estimate the predictive values (positive and negative). Positive predictive value (PPV) is the percentage of people with a positive test who actually have the disease. This provides us with information about the likelihood of the disease being present if the test is positive. Negative predictive value (NPV) is the percentage of people with a negative test who do not have the disease. Increasing the prior probability will increase the PPV but decrease the NPV, assuming that the sensitivity and specificity remain unchanged. Similar changes in the predictive values occur with changes in the prevalence of a condition as will be discussed in screening.

Since validity is measured by sensitivity and specificity and predictive power by PPV and NPV, a major difference in evaluating screening and diagnostic tests is the pre-test probability. Screening, by definition, includes a larger number of individuals without the disease, generally ascertained via a defined population sample. Diagnostic tests are designed to improve clinical diagnoses by enhancing the probability of disease, and by definition the pre-test probability would be high. However, for screening the prior probability is much lower and that effect will lower the PPV. Therefore, screening also requires careful consideration of prevalence, or the prior probability of disease. These analytic methods are now available on many software statistical packages.

The investigator must be clear about the use of the biomarker in the study. Errors are most often made when biomarker data are over interpreted. For example, the results of one study may indicate that a specific biomarker (collected as a measure of an exposure or susceptibility) is strongly associated with a particular disease or outcome. The investigator, on the other hand, interprets the result as a biomarker for the disease or the observed outcome. No matter how high the odds ratio or relative risk, a biomarker of this type could not be expected to function as a diagnostic test unless it is a manifestation of the disease. For example, the APOE-ε4 allele is strongly associated with Alzheimer’s disease, but its presence does not infer disease. Many patients without an APOE-ε4 allele develop Alzheimer’s disease and some individuals with an APOE-ε4 allele do not develop this condition [16,3].

# IX Advantages and Disadvantages of Biomarkers

# The advantages and disadvantages of biomarkers are shown herein in tabulate form.

| **Advantages** | **Disadvantages** |
| --- | --- |
| Objective assessment | Timing is critical |
| Precision of measurement | Expensive (costs for analyses) |
| Reliable; validity can be established | Storage (longevity of samples) |
| Less biased than questionnaires | Laboratory errors |
| Disease mechanisms often studied | Normal range difficult to establish |
| Homogeneity of risk or disease | Ethical responsibility |

**X Limitations of biomarkers alterations**

### **Measurement errors**

Imperfect measurement of the biomarker would naturally lead to deceased validity of the relation to the disease. However, there are numerous types of measurement errors other than those errors that occur in the laboratory.

* Problems with the collection equipment or in the transportation of specimens to the laboratory can affect the measurement of the biomarker.
* Improper storage of samples or changes in storage environment can also affect measurement of biomarkers.
* Technicians are the handlers of most specimens and so appropriate training of new personnel is essential.
* Finally, receipt and control errors such as in the transcription of identification numbers if done by hand can always be source of error.

 A well-organized procedures manual outlining the details for documentation, storage, monitoring of specimens and maintaining records, can alleviate many of these issues. Most laboratories and large-scale studies institute a quality assurance and quality-control program to reduce measurement errors.

### **Bias**

Bias occurs in any study including those with biomarkers.

**Non-Differential Bias**- When biases occur without regard to the outcome, so-called non-differential bias, the effects on the study are less serious but favour the null hypothesis of no association. Problems arise when availability of the biomarker is differentially related to either the disease or the exposure or when the specimen acquisition, storage, measurement, or ascertainment procedures differ in those with the disease compared to those without the disease or outcome of interest.

**Differential Bias** tend to favour an association in either direction, which may not be the true relationship between the biomarker and the disease.

 To reduce such biases, a high response rate from all cases and controls should be maintained and the investigators should have an objective review board review and monitor the conduct of the study, observing possible biases in subject participation or specimen ascertainment.

### **Confounding**

The most important source of confounding is the failure to identify factors that may alter the measurement of the biomarker.

* These can be internal, such as the weight of the subject, or external, such as the batch of laboratory kits used.
* Individual properties of biomarkers should influence the choice and interpretation for its inclusion in any investigation.
* The effects of potential confounders such as age, gender, diet, and other metabolic factors should be investigated before initiating the investigation.
* Biologic stability is critical particularly if the biomarker is to be stored for any length of time.
* Banked serum or plasma is of great value in any study unless it affects the pharmacologic properties of the biomarker. For example, some nutrients such as vitamins do not store well because they are light-sensitive. Storage of all tissues including lymphocytes and extracted DNA can be expensive and the stability of the biomarker studies must be evaluated if storage is required for long intervals.

 These are often overlooked in the analyses and can seriously affect the outcome. One should use data on potential confounders when designing the study and collect relevant internal and external information that might affect the measurement. This information can be included in the analysis of the relation between the biomarker and the outcome of interest.

### **Cost**

The choice of the biomarker for research should be guided by the scientific question and by the financial resources. Cost is always a concern. In a small clinical trial this may be important; if an epidemiologic study includes thousands of subjects the cost can be quite high unless the laboratory procedure is automated and relatively simple. In fact, for some investigations larger sample sizes can bring down the cost per subject. This generally implies that the biomarker is readily available and its inclusion in the study is feasible. For example, automated procedures have made the inclusion of lipid profiles in clinical studies of stroke quite feasible. Methods have improved to the point that a “finger-stick” can provide the necessary amount of blood. Depending on the type of investigation, researchers should have an idea of the false-positive or false-negative profile of the biomarker. As might be expected “false positives” create extra work regardless of whether it is a biomarker of exposure, susceptibility, or disease. “False negatives” simply increase the overall cost of the study. Tolerance for this problem depends on the funding available.

### **Acceptability**

Because biomarkers are derived from human tissues or body fluids, the choice of biomarkers is not trivial. Biomarkers can be also associated with some degree of risk. In clinical trials, this is less a concern because the patient will possibly benefit from the “new treatment.” In quasi-experimental studies, the source of the biomarker may be critical. Body fluids such as blood and urine are usually well tolerated. However, biopsy (particularly of neural tissue) and collection of cerebrospinal fluid are more difficult and associated with slight risks. Risk-benefit will be an issue for the investigator to resolve.

**XI Conclusion**

Biomarkers have a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions.

Many studies using biomarkers never achieve their full potential because of the failure to adhere to the same rules that would apply for the use of variables that are not biological. The development of any biomarker should precede or go in parallel with the standard design of any epidemiological project or clinical trial. In forming the laboratory component, pilot studies must be completed to determine accuracy, reliability, interpretability, and feasibility. The investigator must establish “normal” distributions by important variables such as age and gender. The investigator will also want to establish the extent of intra individual variation, tissue localization, and persistence of the biomarker. Moreover, he or she will need to determine the extent of inter individual variation attributable to acquired or genetic susceptibility. Most, if not all of these issues can be resolved in pilot studies preceding the formal investigation.

Use of biomarkers is particularly important during any pandemic state since they can enhance the development and approval of new, innovative drugs and biological products, particularly in the field of vaccines. Clinical biomarkers are generally defined as the measurable biological indicators of the presence, severity or type of disease in medical settings. Biomarkers can be applied to describe observable characteristics of a certain disease and to determine optimal treatments based on these phenotypes, as well as genotypes, thence, they have received substantial attention. In particular, respiratory disease biomarkers, such as those associated with acute respiratory distress syndrome (ARDS), have been associated with increased mortality (IL-8, ICAM-1) and improved survival (nitric oxide) [17].

**References**

1. BS. Hulka. Overview of biological markers. In: *Biological markers in epidemiology* (Hulka BS, Griffith JD, Wilcosky TC, eds), pp 3–15. New York: Oxford University Press, 1990.

2. S. Naylor. Biomarkers: current perspectives and future prospects. *Expert Rev Mol Diagn* 3: 525–529, 2003.

3. FP. Perera, IB. Weinstein. Molecular epidemiology: recent advances and future directions. *Carcinogenesis* 21: 517–524, 2000.

4. Gordis L. Epidemiology and public policy. In: *Epidemiology* (Gordis L, ed), pp 247–256. Philadelphia: W.B. Saunders, 1996.

5. MM. Verbeek, D. De Jong, HP. Kremer. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. *Ann Clin Biochem* 40: 25–40, 2003.

6 H. Reiber, JB. Peter. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. *J Neurol Sci* 184: 101–122, 2001.

7. R. Mayeux. Biomarkers: potential uses and limitations. NeuroRx. 2004 Apr;1(2):182-8. doi: 10.1602/neurorx.1.2.182. PMID: 15717018; PMCID: PMC534923.

8 K. Strimbu, KA. Tavel. What are biomarkers? Curr Opin HIV AIDS. 2010; 5(6):463e466

9. CC. Dobler. Biomarkers in respiratory diseases. Breathe. 2019; 14(4):265e266

10. KK. Jain. The Handbook of Biomarkers. Springer Publishing Company; 2017.

11. Schulte PA. A conceptual and historical framework for molecular epidemiology. In: *Molecular epidemiology: principles and practices* (Schulte PA, Perera FP, eds), pp 3–44. San Diego: Academic Press, 1993.

12. AIDS Epidemic updat e 2007 WHO

13. PA. Schulte, FP. Perera. Validation. In: *Molecular epidemiology: principles and practices* (Schulte PA, Perera FP, eds), pp 79–107. San Diego: Academic Press, 1993.

14. MS. Pepe, ML. Thompson. Combining diagnostic test results to increase accuracy. *Biostatistics* 1: 123–140, 2000.

15. ML. Thompson, W. Zucchini. On the statistical analysis of ROC curves. *Stat Med* 8: 1277–1290, 1989.

16. R. Mayeux, AM. Saunders, S. Shea et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on apolipoprotein E and Alzheimer’s disease. *N Engl J Med* 338: 506–511, 1998.

17 L. Zhang, H. Guo. Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Adv Biomark Sci Technol. 2020;2:1-23. doi: 10.1016/j.abst.2020.08.001. Epub 2020 Aug 19. PMID: 33511330; PMCID: PMC7435336.